Risk Factors for Palbociclib-Induced Early Developing Neutropenia in Patients with Hormone Receptor-Positive Metastatic Breast Cancer

SIMPLE SUMMARY: Palbociclib, an oral cyclin-dependent kinase 4/6 inhibitor, in combination with endocrine therapy improved outcomes in the metastatic breast cancer patient. Neutropenia (NP) is the most common adverse event, with palbociclib being more frequent among Asians. To date, there is limited...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Yeonhong, Lee, Dayae, Seo, Inyoung, Chae, Heejung, Sim, Sung Hoon, Lee, Keun Seok, Gwak, Hye Sun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216558/
https://www.ncbi.nlm.nih.gov/pubmed/37345147
http://dx.doi.org/10.3390/cancers15102810

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216558/
https://www.ncbi.nlm.nih.gov/pubmed/37345147
http://dx.doi.org/10.3390/cancers15102810

Ejemplares similares